Mechanism for IL-15–Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins
Total Page:16
File Type:pdf, Size:1020Kb
Mechanism for IL-15−Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins This information is current as of September 23, 2021. Rashmi Gupta, Wentian Li, Xiao J. Yan, Jacqueline Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti Rai, Nicholas Chiorazzi and Patricia K. A. Mongini J Immunol 2019; 202:2924-2944; Prepublished online 15 April 2019; Downloaded from doi: 10.4049/jimmunol.1801142 http://www.jimmunol.org/content/202/10/2924 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2019/04/14/jimmunol.180114 Material 2.DCSupplemental References This article cites 125 articles, 55 of which you can access for free at: http://www.jimmunol.org/content/202/10/2924.full#ref-list-1 Why The JI? Submit online. by guest on September 23, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Mechanism for IL-15–Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins Rashmi Gupta,* Wentian Li,* Xiao J. Yan,* Jacqueline Barrientos,† Jonathan E. Kolitz,*,†,‡ Steven L. Allen,*,†,‡ Kanti Rai,*,‡,x Nicholas Chiorazzi,*,‡,x and Patricia K. A. Mongini*,x Clonal expansion of B cell chronic lymphocytic leukemia (B-CLL) occurs within lymphoid tissue pseudofollicles. IL-15, a stromal cell–associated cytokine found within spleens and lymph nodes of B-CLL patients, significantly boosts in vitro cycling of blood- derived B-CLL cells following CpG DNA priming. Both IL-15 and CpG DNA are elevated in microbe-draining lymphatic tissues, and unraveling the basis for IL-15–driven B-CLL growth could illuminate new therapeutic targets. Using CpG DNA-primed human B-CLL clones and approaches involving both immunofluorescent staining and pharmacologic inhibitors, we show that Downloaded from both PI3K/AKT and JAK/STAT5 pathways are activated and functionally important for IL-15→CD122/ɣc signaling in ODN- primed cells expressing activated pSTAT3. Furthermore, STAT5 activity must be sustained for continued cycling of CFSE-labeled B-CLL cells. Quantitative RT-PCR experiments with inhibitors of PI3K and STAT5 show that both contribute to IL-15–driven upregulation of mRNA for cyclin D2 and suppression of mRNA for DNA damage response mediators ATM, 53BP1, and MDC1. Furthermore, protein levels of these DNA damage response molecules are reduced by IL-15, as indicated by Western blotting and immunofluorescent staining. Bioinformatics analysis of ENCODE chromatin immunoprecipitation sequencing data from cell lines http://www.jimmunol.org/ provides insight into possible mechanisms for STAT5-mediated repression. Finally, pharmacologic inhibitors of JAKs and STAT5 significantly curtailed B-CLL cycling when added either early or late in a growth response. We discuss how the IL-15–induced changes in gene expression lead to rapid cycling and possibly enhanced mutagenesis. STAT5 inhibitors might be an effective modality for blocking B-CLL growth in patients. The Journal of Immunology, 2019, 202: 2924–2944. cell chronic lymphocytic leukemia (B-CLL), a disease of This led to the early conjecture that B-CLL results from a gradual the elderly with a median age at diagnosis of 69 y, de- accumulation of clonal cells defective in apoptosis (2). More re- + B velops from a nonmalignant expansion of CD5 B cells cently, heightened research on B-CLL led to the recognition that a by guest on September 23, 2021 that is referred to as monoclonal B cell lymphocytosis. Approxi- sizeable component of each clone undergoes active cycling (3, 4). mately 1–2% of people with this precursor condition require treat- Moreover, the extent of in vivo cycling is linked to patient out- ment for CLL each subsequent year (1). As the elderly population come (5, 6), with the CLL clones bearing IGHV-unmutated Ag increases, B-CLL incidence will undoubtedly rise. The personal and receptors (U-CLL) typically exhibiting faster birth rates than economic costs of living with and treating this malignancy are in- CLL clones bearing IGHV-mutated Ag receptors (M-CLL) (5). centives for continued study into its etiology and unique mecha- Importantly, cycling occurs within lymphoid tissues with a stromal nisms for growth. environment conducive to B-CLL survival and growth (5, 7). The Unlike B cell acute lymphocytic leukemia, which manifests as fact that not all tissue-localized B-CLL cells are undergoing cycling rapidly cycling, bloodborne blasts, B-CLL generally reveals itself suggests that certain stimuli must be encountered for the growth as a slow rise in relatively quiescent CD5+ B cells within blood. response. *The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY 11030; specimens used for this study and edited the paper. P.K.A.M. conceived the exper- †Department of Medicine, Northwell Health, Manhasset, NY 11030; ‡Department of iments, performed certain experiments, analyzed data, and wrote the paper. Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549; and x Address correspondence and reprint requests to Dr. Patricia K. A. Mongini at the Department of Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, current address: Pathogen and Microbiome Institute, Room 156, P.O. Box 4073, Hempstead, NY 11549 Northern Arizona University, Flagstaff, AZ 86011. E-mail address: patricia. ORCIDs: 0000-0002-3717-5803 (X.J.Y.); 0000-0003-2700-4784 (J.E.K.); 0000- [email protected] 0002-3482-3182 (S.L.A.); 0000-0002-5804-2823 (K.R.); 0000-0003-1023- The online version of this article contains supplemental material. 6650 (N.C.); 0000-0002-4966-7741 (P.K.A.M.). Abbreviations used in this article: ATM, ataxia telangiectasia mutated; B-CLL, Received for publication August 17, 2018. Accepted for publication March 13, 2019. B cell chronic lymphocytic leukemia; 53BP1, p53-binding protein 1; ChIP-seq, This work was supported by research funds from Dr. Betty Diamond (The Center for chromatin immunoprecipitation sequencing; chr, chromosome; CLL, chronic lympho- Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute, cytic leukemia; Ct, threshold cycle; CTCF, CCCTC-binding factor; DDR, DNA Manhasset, NY), the National Cancer Institute, National Institutes of Health (NIH) damage response; F, forward; GAS, g-activated sequence; M-CLL, CLL clone (Grant CA08155C4 to N.C.), and the National Institute of Arthritis and Musculo- bearing IGHV-mutated Ag receptors; MDC1, mediator of DNA damage checkpoint skeletal and Skin Diseases, NIH (Grant AR061653 to P.K.A.M.). protein 1; MFI, median fluorescence intensity; ODN, oligodeoxynucleotide; PB, peripheral blood; Q-PCR, quantitative PCR; qRT-PCR, quantitative RT-PCR; R, R.G. performed most in vitro experiments, analyzed data, and edited the paper. W.L. reverse; TBP, TATA box–binding TF; TF, transcription factor; TP53BP1,tumor performed the bioinformatics analysis of ATM, MDC1,andTP53BP1 promoters. protein 53BP1; TSS, transcription start site; U-CLL, CLL clone bearing IGHV- X.J.Y. led the IGHV gene characterization of all B cell chronic lymphocytic leukemia unmutated Ag receptors. (B-CLL) clones. J.B. and J.E.K. provided B-CLL blood specimens and clinical information. S.L.A. and K.R. provided B-CLL blood specimens and clinical infor- Ó mation and edited the paper. N.C. led the acquisition and characterization of B-CLL Copyright 2019 by The American Association of Immunologists, Inc. 0022-1767/19/$37.50 www.jimmunol.org/cgi/doi/10.4049/jimmunol.1801142 The Journal of Immunology 2925 CpG oligodeoxynucleotides (ODN) and IL-15 are two candidate cells did show that IL-15 enhanced the phosphorylation of Shc, stimuli that manifest notable synergy in driving the in vitro cycling ERK, JAK1, JAK3, and STAT5 but not STAT3 or STAT1 (29). of many, albeit not all, blood-derived B-CLL clones (8). Indeed, More recently, it was reported that IL-15 independently activated clonal potential for in vitro ODN + IL-15–driven growth was p38 and STAT5 in naive mouse peritoneal B-1a cells but not statistically linked to clinical outcome in patients with U-CLL (8). conventional B cells (31). Nevertheless, even M-CLL clones, which typically succumb to In this study, ODN-primed B-CLL cells with heightened IL-15R apoptosis following culture with ODN alone (9), show sustained expression are used to examine both early and late events following viability and often extended cycling (six to eight divisions) upon IL-15 signaling. We assess the involvement of PI3K/AKT and culture with both ODN and IL-15 (8). The recent documentation STAT5 pathways in IL-15–driven growth. Furthermore, we in- of IL-15–producing cells within B-CLL–infiltrated spleens (8) vestigate whether these receptor-proximal pathways influence and lymph nodes (10) and in proximity to pseudofollicles (8) mRNA levels for cyclin D2 (important for the G1 to S phase strengthens the possibility that IL-15 fosters B-CLL growth in transition) as well as mRNA/protein for several DNA damage patients. Similar to leukemic incidence, the frequency of IL-15+ response (DDR) molecules important in cell cycle checkpoint stromal cells rises with age (11, 12). Furthermore, CpG DNA is control and DNA repair: ataxia telangiectasia mutated (ATM), available in lymphoid tissues, as microbes drain into these sites, p53-binding protein 1 (53BP1), and mediator of DNA damage and stressed or apoptotic cells are locally produced (8).